Detection of expanded-spectrum cephalosporin hydrolysis by lateral flow immunoassay

Early detection of expanded-spectrum cephalosporin (ESC) resistance is essential not only for an effective therapy but also for the prompt implementation of infection control measures to prevent dissemination in the hospital. We have developed and validated a lateral flow immunoassay (LFIA), called LFIA-CTX test, for the detection of ESC (cefotaxime) hydrolytic activity based on structural discrimination between the intact antibiotic and its hydrolysed product. A single bacterial colony was suspended in an extraction buffer containing cefotaxime. After a 30-min incubation, the solution is loaded on the LFIA for reading within 10 min. A total of 348 well-characterized Gram-negative isolates were tested. Among them, the 38 isolates that did not express any cefotaxime-hydrolysing beta-lactamase gave negative results. Of the 310 isolates expressing at least one cefotaxime-hydrolysing beta-lactamase, all were tested positive, except three OXA-48-like producers, which were repeatedly detected negative. Therefore, the sensitivity was 99.1% and the specificity was 100%. The LFIA-CTX test is efficient, fast, low-cost and easy to implement in the workflow of a routine microbiology laboratory.

Automated summary

The LFIA-CTX test is a highly efficient, rapid, low-cost lateral flow immunoassay method for detecting expanded-spectrum cephalosporin (ESC) hydrolytic activity. The results demonstrate the high sensitivity and specificity of this method for detecting cefotaxime-hydrolysing beta-lactamase, making it easy to implement in routine microbiology labs.